Eleven patients with hematologic malignancies and two with aplastic anemia were treated using unmanipulated marrow and immunoselected CD34 ؉ blood cells. Donors began G-CSF (10 g/kg) injections 1 day after undergoing bone marrow harvest. Blood stem cells were collected on day 5 of G-CSF. Peripheral blood lymphocytes were depleted via CD34-positive selection. If, after marrow and blood harvest, less than 2.0 ؋ 10 6 CD34 cells/kg were mobilized, leukapheresis was repeated on day 6. Median time to an absolute neutrophil count greater than 500 l was day 10; transfusion-independent platelet count greater than 20 000/l was day 13; average hospital discharge was day 14; and average inpatient hospital charges were 101 870 US dollars. Acute GVHD grade II occurred in five of 13 patients. No patient developed grade III or IV acute GVHD. At a median follow-up of 10 months, no patient has developed extensive chronic GVHD. Allografts of unmanipulated bone marrow supplemented with G-CSF-mobilized and CD34 immunoselected blood cells may prevent an increased risk of GVHD while preserving the rapid engraftment kinetics of peripheral blood. Supplementation of marrow with CD34 enriched blood cells appears to result in rapid engraftment, early hospital discharge, lower inpatient charges, decreased regimen-related toxicity, and no apparent increase in GVHD.
fore undertaken a feasibility study using the combination of unmanipulated marrow and CD34 enriched PBSCs for allogeneic engraftment. Supplementation of an unmanipulated marrow harvest with CD34 enriched (lymphocyte depleted) peripheral blood stem cells should in theory provide rapid engraftment, without increasing GVHD, graft failure, or relapse rate.
Methods

Patients
Between January 1997 and February 1998, 15 patients (age 24-56 years old) received unmanipulated marrow and CD34 enriched peripheral blood cells from genotypically HLA-matched siblings. In contrast to the other cases, two patients were not given anti-bacterial and anti-fungal prophylaxis. Both of these patients died from septic multiorgan failure occurring within the first week of stem cell reinfusion and are excluded from subsequent analysis. Candidates must have met the eligibility requirements of any Northwestern University IRB approved allogeneic bone marrow transplantation protocol for leukemia, lymphoma, myeloma, or aplastic anemia. If criteria for the primary bone marrow transplantation protocol were fulfilled, candidates were offered an adjunct protocol to augment donor bone marrow with CD34 enriched peripheral blood stem cells. The secondary protocol for CD34 enriched peripheral blood stem cells is US FDA approved under investigational device exception number BB-IDE 6991.
Supportive care
Patients were treated on a hepa-filtered but otherwise general hematology/oncology service. A low microbial diet, fluconazole (400 mg/day oral or intravenous), valacyclovir (500 mg three times a day oral or intravenous), and ursodiol (300 mg p.o. three times a day) were started on admission and discontinued when the ANC rebounded to 500/l. Oral ciprofloxacin (750 mg orally twice a day) was started on admission and switched to intravenous piperacillin/ tazobactam when the absolute neutrophil count fell below 500/l. Whilst neutropenic, patients were confined to their rooms. Hand washing and gloves were required for all personnel entering a patient's room. Subcutaneous G-CSF (5 g/kg) was started the day of hematopoietic stem cell infusion and continued until the ANC was greater than 1000/l for 3 consecutive days.
Stem cell collection
Donor marrow was harvested under general anesthesia and cryopreserved in liquid nitrogen. The following day 10 g/kg/day of G-CSF (Amgen, Thousand Oaks, CA, USA) was given subcutaneously. A 10-15 l leukapheresis was performed on day 5 of G-CSF. If a minimum of 2.0 ϫ 10 6 CD34 cells/kg were not available after marrow and blood harvest a second PBSC collection was performed on day 6.
CD34 enrichment
To diminish the risk of increasing GVHD, the peripheral blood stem cell harvest was lymphocyte depleted by CD34-positive selection using the CellPro CEPRATE immunoadsorption column (Bothel, WA, USA). The enriched stem cell fraction was cryopreserved in the vapor phase of liquid nitrogen.
Conditioning regimens
Regimens for hematologic malignancies included: busulfan (14 mg/kg) and cyclophosphamide (120-200 mg/kg); cyclophosphamide (120 mg/kg) and total body irradiation (1200 cGy); or busulfan (14 mg/kg), etoposide (20 mg/kg), and cyclophosphamide (120 mg/kg). The conditioning regimen for aplastic anemia was cyclophosphamide (200 mg/kg) and anti-thymocyte globulin (90 mg/kg).
GVHD prophylaxis
To prevent GVHD, patients received prophylaxis with cyclosporine (CsA) and corticosteroids. CsA was started on day Ϫ1 at 5 mg/kg/day infused intravenously over 24 h. CsA was switched to oral twice a day dosing when the ANC was Ͼ500 l. Dosage was adjusted to maintain CsA levels at 150-250 ng/ml by HPLC. Corticosteroids were started on day 7 as either an intravenous methylprednisolone or equivalent oral prednisone dose of 0.5 mg/kg/day. Corticosteroids were increased to 1.0 mg/kg/day on day 15 then tapered weekly as follows: 0.8 mg/kg/day on day 22; 0.5 mg/kg/day on day 29; 0.4 mg/kg/day on day 36; 0.2 mg/kg/day on day 43; 0.1 mg/kg/day on day 56, then discontinued.
Results
Stem cell collection
Of the 13 donors, two required a second leukapheresis on day 6 to collect more than 2.0 ϫ 10 6 CD34 ϩ cells after enrichment. Mean percent recovery of CD34 ϩ cells in the enriched fraction was 59%. A mean of 5.3 ϫ 10 6 CD34 ϩ cells/kg was infused from the combined marrow and PBSC graft. Peripheral blood contributed 58% of the infused CD34 ϩ progenitor cells (Table 1) . A mean of 4.1 ϫ 10 7 T cells/kg were infused. After CD34 enrichment, the donor's peripheral blood contributed a mean of 0.067 ϫ 10 7 T cells/kg or 1.6% of the infused T cells.
Hematologic recovery
Engraftment defined as an absolute neutrophil count greater than 500/l occurred on day 10 ( Table 2 ). The average duration of a neutrophil count less than 500/l was 8 days. A platelet count greater than 20 000 without transfusions occurred on day 13. Rapid engraftment resulted in diminished RBC and platelet transfusion requirements. The median numbers of RBC and platelet transfusions were 3 and 5, respectively. In some patients, a transient fall of platelet counts which did not require transfusions occurred 3-4 weeks after stem cell infusion. Two patients had transient graft suppression after surveillance pre-emptive ganciclovir therapy following positive CMV surveillance cultures. Counts recovered after discontinuing ganciclovir and starting a short course of G-CSF.
Toxicity/Infection
Donors tolerated marrow harvest and peripheral blood stem cell collections without unanticipated or significant toxicity. Mild arthralgias secondary to G-CSF required acetaminophen in some donors. Most recipients experienced no significant regimen-related toxicities ( Table 3 ). The clinical course was notable for absence of mucositis, veno-occlusive disease, interstitial pneumonitis, and in some cases, absence of fever or necessity for parenteral nutrition. The only positive cultures were from central line-related Staphylococcus epidermidis. Within the first 120 days, two patients developed positive shell vials for CMV without clinical signs. Both were treated with pre-emptive ganciclovir.
GVHD
Eight of 13 patients developed grade I or II acute GVHD.
No patients developed grade III or IV acute GVHD. All patients with grade II acute GVHD responded to high-dose methylprednisolone (1 g ϫ 3 days) followed by a rapid taper. Limited chronic GVHD developed in five patients.
Financial charges
For these 13 patients, average inpatient hospital charges were $101 890. Itemized charges (Table 4) were $25 021 for room and nursing care; $44 723 for pharmaceutical drugs and infusions; $7908 for blood products; and $12 281 for laboratory and radiographs.
Discussion
Due to rapid engraftment, peripheral blood stem cells have replaced bone marrow as the most common source of progenitor cells in autologous transplantation. In allogeneic transplantation, the immunologic mismatch between recipient and donor and the larger number of T cells in peripheral blood compared to bone marrow may increase the risk of GVHD. [1] [2] [3] [4] Both acute and chronic GVHD were more frequent in patients with aplastic anemia following infusion of combined marrow and buffy coat lymphocytes compared to those given marrow alone. 8 Unmodified peripheral blood AA = aplastic anemia; AML = acute myeloid leukemia; ANC = absolute neutrophil count; CML = chronic myeloid leukemia; CTCL = cutaneous T cell lymphoma; MM = multiple mycloma; PRBC = packed red blood cells.
grafts contain approximately a log more T cells than unmanipulated marrow grafts. Although sometimes conflicting, early retrospective analysis involving small numbers of patients suggests that compared to marrow, a blood graft does not appear to affect the incidence or severity of acute GVHD. [9] [10] [11] [12] [13] [14] [15] [16] [17] However, several studies report a higher incidence of chronic GVHD. [1] [2] [3] [4] Increased chronic GVHD after allogeneic PBSC transplantation may be avoided by depleting the graft of lymphocytes. 18, 19 The advantageous effect of non-selective lymphocyte depletion on GVHD may, however, be offset by increased graft failure and relapse rates. A significant relapse rate and increased late graft failure has been reported after allogeneic lymphocyte-depleted PBSC transplantation for aggressive lymphomas. 19 Besides CD34 ϩ cells, other components such as T and NK cells and marrow-specific components such as stromal cells or matrix may contribute to long-term engraftment. The disadvantage of a marrow graft is relatively slow engraftment with increased regimen-related and infectious complications. The disadvantage of a blood graft is an increased risk of chronic GVHD. The disadvantage of lymphocyte depletion is graft failure, relapse, and impaired immune reconstitution. In order to conserve the beneficial long-term engraftment kinetics and low relapse rate of marrow and take advantage of rapid blood stem cell engraftment while avoiding an increased risk of chronic GVHD, unmanipulated marrow was supplemented with CD34 enriched PBSC. Engineering a graft to supplement unmanipulated marrow with CD34 enriched filgrastimmobilized blood stem cells appears to minimize the disadvantages inherent to each stem cell source. AA = aplastic anemia; AML = acute myeloid leukemia; Bu = busulfan; CML = chronic myeloid leukemia; CTCL = cutaneous T cell lymphoma; Cy = cyclophosphamide; GVHD = graft-versus-host disease; MM = multiple myeloma; TBI = total body irradiation. Despite small numbers, the incidence of GVHD is no worse and, as data accumulate, may be better than with a marrow graft alone. It is difficult to draw any conclusion on GVHD in our series of 13 patients. However, Deeg et al 20 reported an incidence of acute GVHD grade III-IV of 34% and chronic GVHD of 44% in adult patients undergoing marrow transplant using cyclosporine and methylprednisolone prophylaxis. We also used cyclosporine and methylprednisolone for GVHD prophylaxis. Our results using marrow supplemented with CD34 enriched PBSCs do not suggest an increased incidence of acute GVHD. In fact, no patient had grade III or IV acute GVHD. Following high-dose chemoradiotherapy, prolonged neutropenias, persistent fever, delayed tissue repair with presentation of cryptic or hidden antigens, and a cytokine storm may all in theory contribute to GVHD. These consequences would be minimized by rapid engraftment. Other possible explanations for a low incidence of acute GVHD may be related to use of broad-spectrum antibiotics when the ANC fell below 500/l. Prophylactic antibiotics may decrease proinflammatory cytokines from non-specific bacterial activation of immunity. The increased stem cell dose may also decrease GVHD. [21] [22] [23] In haploidentical transplants, GVHD has been reported to be decreased by megadose (Ͼ10 7 /kg) progenitor cells. 21 This progenitor cell 'tolerance or veto effect' has been postulated to be due to stem cell antigen presentation without costimulation. 23 Finally, the marrow product was cryopreserved which, although unproven, may have diminished GVHD.
In terms of engraftment, our results appear superior to other studies involving CD34 selected cells. As mentioned previously, Mavroudis et al 19 reported an increase in late graft failure with infusion of only CD34 selected PBSC transplants. Link et al 24 reported that combined transplantation of allogeneic marrow and CD34 enriched blood cells resulted in a median time to engraftment (neutrophils Ͼ500/l) of 15 days. Cyclosporine and short-course methotrexate were used for GVHD prophylaxis. In contrast, our study used cyclosporine and methylprednisolone for GVHD prophylaxis. 20 Avoidance of methotrexate may have contributed to the more rapid engraftment kinetics in our study (neutrophils Ͼ500/l on day 10). Hassan et al 25 reported infusion of combined BM and PBSC both of which were CD34 selected in four patients. The times to an ANC Ͼ500/l and platelet count greater than 20 000/l were days 18 and 28. respectively. In six other patients, either CD34 selected marrow or CD34 selected PBSC were infused with even slower kinetics of engraftment (ANC Ͼ500/l and platelet count Ͼ20 000/l on days 21 and 38, respectively). In the Hassan study, the low number of T cells infused with the CD34 enriched grafts and the use of methotrexate GVHD prophylaxis may have contributed to slower engraftment compared to our study. In our trial the marrow is not depleted of T cells, only the PBSC graft is CD34 enriched. Nemunaitis et al 26 reported decreased early morbidity by combining unmanipulated allogeneic marrow and unmanipulated PBSCs. However, this was a single case report and the patient died on day 113 from relapsed leukemia.
Aversa et al 27 reported infusion of T cell-depleted megadose CD34
ϩ cells (approximately 10 7 CD34 cells/kg) using combined PBSC and marrow from HLA-mismatched related donors. Engraftment kinetics were similar to our study. However, several patients died from opportunistic infections, especially of CMV and fungus. Therefore, a 7-to 10-fold increase in CD34
ϩ progenitor cells appears to overcome the delayed engraftment associated with aggressive T cell depletion. However, patients suffered from poor immune reconstitution and lethal opportunistic infections. In our trial, which involved HLA-matched siblings, the marrow was not T cell depleted and no late opportunistic infections have occurred.
Despite rapid engraftment, life-threatening infections may still occur during the interval of neutropenia. Initially, concerns about development of resistant organisms prevented use of prophylactic antibiotics. Two patients were not treated with prophylactic antibiotics and were excluded from analysis. One patient presented on day 6 with fever and refractory hypotension. Multiple blood cultures were positive for Streptococcus pneumoccocci. Despite recovery of neutrophils on day 9, the patient subsequently died from sepsis-related multi-organ failure. A second patient did not enter remission for a refractory and heavily pretreated lymphoma and died from disseminated aspergillosis and Hemophilus influenza pneumonia. Subsequently, all patients were started on oral ciprofloxacin upon admission and switched to intravenous piperacillin/tazobactam when the ANC fell below 500/l regardless of fever. No further bacterial septic episodes occurred and no antimicrobial resistant organisms were isolated.
Regimen-related toxicities were relatively insignificant. Minimal regimen-related complications may have been secondary to dosing chemotherapy by the lesser of ideal or actual weight, relatively high stem cell dose, and/or avoidance of methotrexate. Rapid engraftment from a large stem cell dose correlates inversely with regimen-related toxicities. GVHD prophylaxis with methotrexate may also increase both mucositis and veno-occlusive disease. Substitution of corticosteroids instead of methotrexate for GVHD prophylaxis may have contributed to less toxicity.
Although a retrospective comparison was not performed, the financial charges of transplantation using the combination of marrow and CD34 selected blood cells were substantially below our anticipated charges for allogeneic bone marrow transplantation. We did not include the charges of stem cell collection using two procedures, marrow harvest and PBSC mobilization. Most transplant recipients are currently charged for either marrow or PBSC mobilization. Therefore, our method would add the charges of one additional stem cell collection procedure. The savings were due to early hospital discharge and decreased pharmaceutical and blood product requirements. Since it is unclear if post-infusion G-CSF will affect engraftment kinetics of donor G-CSF-mobilized blood stem cells, further reductions in charges may be obtained by omitting recipient growth factor treatment following stem cell infusion. Laboratory charges may also be reduced by omitting our current practice of obtaining routine but clinically unindicated tests such as weekly chest radiographs or daily hematology and chemistry panels. Optimizing the stem cell component of a graft may allow rapid engraftment and a low incidence and severity of GVHD and regimen-related complications. This may allow for even further reduction in charges by performing allogeneic transplantation in an outpatient setting.
